Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02108652 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | completed | Phase 2 | 310 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT02951767 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | completed | Phase 2 | 119 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03433924 | An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.(POLARIS) | completed | — | 248 | AstraZenecaINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05822518 | Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy | completed | N/A | 42 | Menoufia UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02145871 | A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy | completed | Phase 3 | 282 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03892642 | Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer(OU-SCC-ABC) | completed | Phase 1 / Phase 2 | 18 | University of OklahomaOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06235853 | Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer | completed | — | 240 | Wroclaw Medical UniversityOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03962933 | Urine-based Detection of Non-muscle Invasive Bladder(SOLUSION) | completed | — | 196 | Nessn AzawiOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06205277 | Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer(START) | completed | — | 1,300 | University of TriesteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06193941 | Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits | completed | — | 400 | Zhongnan HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02676180 | Detecting Bladder Cancer Using the UroMark Test.(DETECT I) | completed | — | 3,700 | University College, LondonOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06156787 | Patterns of Urinary Bladder Cancer in Darfur, Suda | completed | — | 105 | National Center for Gastroentestinal and Liver DiseaseOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02781428 | To Detect the Sensitivity of the UroMark Assay(DETECT II) | completed | — | 1,643 | University College, LondonOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05154084 | RESECT: Improving Quality in TURBT Surgery.(RESECT) | completed | — | 19,505 | British Urology Researchers in Surgical TrainingOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03998579 | Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer(CanMoRe) | completed | N/A | 100 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04534309 | Behavioral Weight Loss Program for Cancer Survivors in Maryland(ASPIRE) | completed | N/A | 340 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02643043 | UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | completed | N/A | 219 | Matthew Milowsky, MDOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04994639 | Hypotension Prediction Effect on AKI | completed | N/A | 120 | Ewha Womans University Mokdong HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02722538 | Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer | completed | Phase 1 | 23 | Taris Biomedical LLCINDUSTRY | 2 | Sep 18, 2023 | clinicaltrials |
| NCT04475029 | Methadone in Cystectomy Patients(METAMORF) | completed | N/A | 114 | University of AarhusOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06020807 | Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer | completed | — | 168 | Nucleix Ltd.INDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05025748 | Ask Questions (ASQ):Implementation of a Communication Intervention | completed | N/A | 81 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03636256 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 36 | NanOlogy, LLCINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02756637 | Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710 | completed | — | 634 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG(VISTA) | completed | Phase 3 | 133 | Sesen Bio, Inc.INDUSTRY | 2 | Jul 24, 2023 | clinicaltrials |
| NCT05946369 | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | completed | — | 96 | Ain Shams UniversityOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05937555 | Professional Bladder Cancers and the Profession of Painter(NEVPP) | completed | — | 150 | University Hospital, BrestOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT00002914 | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract | completed | Phase 2 | 40 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00003129 | Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | completed | Phase 2 | 75 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003376 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 3 | 330 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005644 | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00053209 | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT04311580 | Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure | completed | Phase 2 | 52 | University of Rome Tor VergataOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT00004223 | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00002520 | Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer | completed | N/A | 434 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00003701 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 490 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03852030 | Mind-Body Health in Uro-Oncology: Research Study | completed | N/A | 120 | Northwestern UniversityOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05400291 | Gag-layer in the Urothelium of the Human Upper Urinary Tract | completed | — | 16 | Aarhus University HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2024source: clinicaltrials